三金SANJIN品牌怎么样 申请店铺

我要投票 三金SANJIN在口气清新剂行业中的票数:975 更新时间:2026-01-12
三金SANJIN是哪个国家的品牌?「三金SANJIN」是 桂林三金药业股份有限公司 旗下著名品牌。该品牌发源于广西,由创始人邹节明在1994期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力三金SANJIN品牌出海!将品牌入驻外推网,定制三金SANJIN品牌推广信息,可以显著提高三金SANJIN产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

三金SANJIN怎么样

桂林三金药业股份有限公司是三金集团的核心企业,主营中成药、天然药物的研发和生产,是国内较早生产现代中药制剂的厂家之一,也是广西医药龙头企业。1985年以来,桂林三金坚持改革创新,依靠科技进步和科学管理,从一个名不见经传的中药作坊小厂蜕变成为全国知名的现代中药企业。

三金作为区内外知名的高新技术企业,建有国家认定的企业技术中心、博士后科研工作站及广西中药产业化工程院等创新平台。多年来,一直致力推进和实施中药产业现代化规划,积极培养、提高企业的自主创新能力。目前公司的特色中药新药均由企业技术中心主导研制。目前,三金拥有200多个注册品种和13个药品剂型,拥有桂林西瓜霜、西瓜霜润喉片、三金片、脑脉泰胶囊等自主开发的特色品种42种。经过多年努力,三金在咽喉、口腔用药和泌尿系统用药方面已形成较强的专业和市场优势,代表产品三金西瓜霜系列、三金片。“三金”牌产品已行销海内外,并享有良好声誉。

2009年7月,桂林三金以高成长、高效益的崭新面貌,成功进入资本市场,迎来企业高速发展的新阶段。近年来,为积极响应桂林市委、市政府“向西发展,再造一个新桂林”的号召,也为解决企业生产基地及仓储设施分散与企业快速发展之间的矛盾,三金启动了“三金现代中药产业化技术改造工程”的建设。目前,该项目一期已经正式投产并实现了主要生产线的整体搬迁。

面对未来,三金将秉承“创新推动医药进步”的企业使命和“敢为先”企业精神,实施以中药制药为主体,致力发展生物制药和大健康产业的”一体两翼”发展战略,视质量、信誉为企业第一生命,突破创新,不断增强三金的竞争实力,锐意进取,以发展报国、回报投资者,以打造中国知名医药制造集团为目标,推动中药产业现代化、国际化!


Guilin Sanjin Pharmaceutical Co., Ltd. is the core enterprise of Sanjin group, which is mainly engaged in the research and development and production of Chinese patent medicine and natural medicine. It is one of the earliest manufacturers of modern Chinese medicine preparations in China, and also the leading enterprise of Guangxi medicine. Since 1985, Guilin Sanjin has persisted in reform and innovation, relying on scientific and technological progress and scientific management, and has transformed from an unknown small traditional Chinese medicine workshop into a well-known modern Chinese medicine enterprise in China. As a well-known high-tech enterprise inside and outside the zone, Sanjin has established a national recognized enterprise technology center, postdoctoral research workstation, Guangxi Institute of traditional Chinese medicine industrialization and other innovation platforms. Over the years, we have been committed to promoting and implementing the modernization plan of traditional Chinese medicine industry, and actively cultivating and improving the independent innovation ability of enterprises. At present, the company's characteristic new Chinese medicine is mainly developed by the enterprise technology center. At present, Sanjin has more than 200 registered varieties and 13 pharmaceutical dosage forms, and 42 self-developed characteristic varieties such as Guilin Watermelon cream, watermelon cream throat moistening tablet, Sanjin tablet, Naomaitai Capsule, etc. After years of efforts, Sanjin has formed strong professional and market advantages in throat, oral medicine and urinary system medicine, representing Sanjin watermelon cream series and Sanjin tablets. "Three gold" brand products have been sold at home and abroad, and enjoy a good reputation. In July 2009, Guilin Sanjin successfully entered the capital market and ushered in a new stage of rapid development of enterprises with a new look of high growth and high efficiency. In recent years, in order to actively respond to the call of Guilin municipal Party committee and municipal government to "develop to the West and rebuild a new Guilin", and to solve the contradiction between the scattered production base and storage facilities of enterprises and the rapid development of enterprises, Sanjin has launched the construction of "Sanjin modern Chinese medicine industrialization technology transformation project". At present, the first phase of the project has been officially put into operation and the overall relocation of the main production lines has been realized. In the future, Sanjin will adhere to the enterprise mission of "innovation promotes pharmaceutical progress" and the enterprise spirit of "dare to be the first", implement the development strategy of "one body and two wings" with traditional Chinese medicine as the main body, devote to the development of biopharmaceutical and big health industry, regard quality and reputation as the life of the enterprise, break through innovation, continuously enhance the competitiveness of Sanjin, forge ahead, serve the country and return with development Newspaper investors, with the goal of building a well-known Chinese pharmaceutical manufacturing group, to promote the modernization and internationalization of traditional Chinese medicine industry!

本文链接: https://brand.waitui.com/7e6028fbc.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

金价银价大幅波动原因,多家机构预计贵金属今年仍有上涨空间

华尔街投行高盛指出,预计相较黄金交易来说,白银交易将持续面临高波动性和不确定性。综合多家金融机构的分析来看,本周有两个因素加剧了贵金属价格的下行压力。一是彭博大宗商品指数本周启动年度再平衡调整,贵金属权重被大幅下调,分析人士称,预计这次再平衡调整会触发指数追踪型资金被动减仓,使得黄金和白银面对获利了结压力。二是芝商所集团从周五盘后起,再次上调黄金、白银、铂金和钯金等贵金属期货履约保证金,这是最近一个月以来,芝商所集团第三次上调贵金属期货保证金。(央视财经)

56分钟前

2025年上合示范区中欧班列开行量和货运量再创新高

青岛海关消息,2025年,青岛海关监管上合示范区到发中欧班列1225列、进出口货物84万吨,班列开行量和货运量均增长超两成,创历史同期新高。上合示范区启动建设以来,已累计到发中欧班列5491列,发运集装箱45万标箱,运送进出口货物380万吨。(央视新闻)

56分钟前

印度拟要求智能手机制造商向政府共享源代码 遭苹果三星等反对

印度拟出台多项安全措施,要求智能手机制造商向政府共享源代码并对软件进行多项修改,此举引发苹果、三星等科技巨头的私下反对。据四名知情人士透露,以及对政府和行业机密文件的核查结果显示,上述措施包含 83 项安全标准,其中还要求企业在推送重大软件更新时向政府报备。这些科技企业反驳称,这套安全标准在全球范围内尚无先例可循,且存在泄露企业专有信息的风险。(财联社)

56分钟前

仙坛股份:2025年12月鸡肉产品销售收入增长9.41%

36氪获悉,仙坛股份公告,公司2025年12月实现鸡肉产品销售收入5.29亿元,销售数量5.51万吨,同比变动分别为9.41%和6.76%。

56分钟前

达尔环球公司与特朗普集团将启动价值100亿美元的新沙特房地产项目

达尔环球CEO表示,达尔环球公司与特朗普集团将启动价值100亿美元的新沙特房地产项目。(财联社)

56分钟前

本页详细列出关于三金SANJIN的品牌信息,含品牌所属公司介绍,三金SANJIN所处行业的品牌地位及优势。
咨询